CD3-CM201-100μg / 询价
CD3-CM201-500μg / 询价
CD3-CM201-500μgx2 / 询价
- 客服电话
- 技术支持
Cynomolgus CD3E&CD3D/CD3 epsilon&CD3 delta Protein
Recombinant Cynomolgus CD3E&CD3D/CD3 epsilon&CD3 delta Protein is expressed from HEK293 with hFc tag at the C-Terminus.It contains Gln22-Asp117(CD3E)&Phe22-Ala105(CD3D) [Accession | Q95LI5.2 (CD3E)&Q95LI8 (CD3D)].
The protein has a predicted MW of 36.9 kDa (CD3E) and 35.4 kDa (CD3D). Due to glycosylation,the protein migrates to 58-62 kDa (CD3E) and 44-46 kDa (CD3D) based on Bis-Tris PAGE result.
>95% as determined by Bis-Tris PAGE
>95% as determined by HPLC
Less than 1 EU per μg by the LAL method.
Lyophilized from 0.22 μm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.
-20 to -80°C for 12 months as supplied from date of receipt.
-80°C for 3 months after reconstitution.
Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
Cynomolgus CD3E&CD3D on Bis-Tris PAGE under reduced conditions. The purity is greater than 95%.
The purity of Cynomolgus CD3E&CD3D was greater than 95% as determined by SEC-HPLC.
Immobilized Cynomolgus CD3E&CD3D, hFc Tag at 0.5 μg/ml (100 μl/Well). Dose response curve for Biotinylated Anti-CD3E&CD3D Antibody, hFc Tag with EC50 of 52.6 ng/ml determined by ELISA.
T-cell surface glycoprotein CD3 epsilon&CD3 delta chain, also known as CD3E&CD3D, are single-pass type I membrane proteins. When antigen presenting cells (APCs) activate T-cell receptor (TCR), TCR-mediated signals are transmitted across the cell membrane by the CD3 chains CD3D, CD3E, CD3G and CD3Z. All CD3 chains contain immunoreceptor tyrosine-based activation motifs (ITAMs) in their cytoplasmic domain.
CD3; CD3e; CD3E; CD3d; T3D; CD3D; CD3E&CD3D; CD3 delta&CD3 epsilon
Penaranda C , Tang Q , Bluestone J A. Anti-CD3 Therapy Promotes Tolerance by Selectively Depleting Pathogenic Cells while Preserving Regulatory T Cells[J]. The Journal of Immunology, 2011, 187(4):2015-2022.
